JPH01172334A - Preventive and remedy for swine pasteurellosis - Google Patents
Preventive and remedy for swine pasteurellosisInfo
- Publication number
- JPH01172334A JPH01172334A JP62328322A JP32832287A JPH01172334A JP H01172334 A JPH01172334 A JP H01172334A JP 62328322 A JP62328322 A JP 62328322A JP 32832287 A JP32832287 A JP 32832287A JP H01172334 A JPH01172334 A JP H01172334A
- Authority
- JP
- Japan
- Prior art keywords
- crude drug
- rhizome
- orientalis
- water
- pigs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003449 preventive effect Effects 0.000 title claims abstract description 11
- 206010034107 Pasteurella infections Diseases 0.000 title claims description 16
- 201000005115 pasteurellosis Diseases 0.000 title claims description 16
- 241000282898 Sus scrofa Species 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 39
- 229940079593 drug Drugs 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000003960 organic solvent Substances 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 9
- 244000025221 Humulus lupulus Species 0.000 claims abstract description 9
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 9
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 9
- 241000282887 Suidae Species 0.000 claims description 27
- 241000411851 herbal medicine Species 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 16
- 239000004615 ingredient Substances 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- 244000299790 Rheum rhabarbarum Species 0.000 claims description 10
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 8
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 8
- 229940010454 licorice Drugs 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 230000000069 prophylactic effect Effects 0.000 claims description 7
- 241001116389 Aloe Species 0.000 claims description 6
- 241000202807 Glycyrrhiza Species 0.000 claims description 6
- 235000011399 aloe vera Nutrition 0.000 claims description 6
- 241001369972 Deudorix epijarbas Species 0.000 claims description 4
- 241000756137 Hemerocallis Species 0.000 claims description 4
- 239000011046 carnelian Substances 0.000 claims description 4
- 241000985665 Cecropia obtusifolia Species 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 235000008694 Humulus lupulus Nutrition 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 241000283690 Bos taurus Species 0.000 abstract description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 3
- 240000007474 Aloe arborescens Species 0.000 abstract description 2
- 235000004509 Aloe arborescens Nutrition 0.000 abstract description 2
- 241001183967 Isodon Species 0.000 abstract description 2
- 244000184734 Pyrus japonica Species 0.000 abstract description 2
- 235000009508 confectionery Nutrition 0.000 abstract description 2
- 241000218203 Coptis japonica Species 0.000 abstract 2
- 244000144994 Galla Rhois Species 0.000 abstract 2
- 241000972673 Phellodendron amurense Species 0.000 abstract 2
- 240000001745 Rheum palmatum Species 0.000 abstract 2
- 235000008090 Rheum palmatum Nutrition 0.000 abstract 2
- 241000759833 Cornus officinalis Species 0.000 abstract 1
- 235000011158 Prunus mume Nutrition 0.000 abstract 1
- 244000018795 Prunus mume Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 244000173853 Sanguisorba officinalis Species 0.000 abstract 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 abstract 1
- 210000003813 thumb Anatomy 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 206010035664 Pneumonia Diseases 0.000 description 9
- 241000606860 Pasteurella Species 0.000 description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 244000105059 Geranium thunbergii Species 0.000 description 5
- 235000005491 Geranium thunbergii Nutrition 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000004515 gallic acid Nutrition 0.000 description 4
- 229940074391 gallic acid Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- -1 n -Propertool Chemical compound 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007799 cork Substances 0.000 description 3
- 239000008141 laxative Substances 0.000 description 3
- 230000002475 laxative effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- SCCDQYPEOIRVGX-UHFFFAOYSA-N Acetyleugenol Chemical compound COC1=CC(CC=C)=CC=C1OC(C)=O SCCDQYPEOIRVGX-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 241001124076 Aphididae Species 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- VGKXEMCICHSUIU-QYYRPYCUSA-N (2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-iodooxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1I VGKXEMCICHSUIU-QYYRPYCUSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 244000296825 Amygdalus nana Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 241000003910 Baronia <angiosperm> Species 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241001365032 Isodon trichocarpus Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- 206010035702 Pneumonia haemophilus Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 235000009430 Thespesia populnea Nutrition 0.000 description 1
- 241000269841 Thunnus albacares Species 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 239000010330 ougon Substances 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は、豚のパスツレラ症の予防及び治療剤並びに予
防及び治療方法に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a prophylactic and therapeutic agent and a prophylactic and therapeutic method for pasteurellosis in pigs.
さらに詳しくは、本発明は、細菌Pa5teurel
Ia1ultOc1daによる豚の感染症であるパスツ
レラ症の生薬を用いる予防及び治療剤並びに予防及び治
療方法に関する。More specifically, the present invention relates to the bacterium Pa5teurel.
The present invention relates to preventive and therapeutic agents and preventive and therapeutic methods using crude drugs for pasteurellosis, which is an infectious disease of pigs caused by IaultOc1da.
〔従来の技術]
豚のパスツレラ症は、豚の細菌性伝染病の1つで、病原
菌はPa5teurella 5ultocldaであ
る◎発生率、死亡率ともに高く、養豚業に与える産業的
被害も大きいことから、豚の数ある疾病の中でもその防
除対策の確立が急がれる最も重要な疾病の1つである。[Prior art] Pasteurellosis of pigs is one of the bacterial infectious diseases of pigs, and the pathogen is Pa5teurella 5ultoclda ◎Since both the incidence and mortality rate are high and the industrial damage caused to the pig farming industry is large, Among the many diseases in the world, it is one of the most important diseases for which it is urgently necessary to establish control measures.
本疾病は肺炎を主機とする。ヘモフィルス肺炎の症状と
似ており、混合感染する場合もある。この菌はもともと
健康な豚の上部気道粘膜にも存在することがあるが、動
物側に何らかの誘因、例えば軽度の呼吸器感染や長途の
輸送などが加わったときに、病原性を示すようになる。This disease is mainly caused by pneumonia. Symptoms are similar to those of Haemophilus pneumonia, and mixed infections may occur. This bacterium can originally exist in the upper respiratory tract mucosa of healthy pigs, but it becomes pathogenic when the animal is exposed to some kind of trigger, such as a mild respiratory tract infection or long-distance transport. .
また流行性肺炎や萎縮性鼻炎等の他の呼吸器疾患に対し
て二次感染する場合もある。In addition, secondary infections may occur due to other respiratory diseases such as epidemic pneumonia and atrophic rhinitis.
本疾病のうち経過の急性なものでは40〜42℃の発・
熱がみられ、発症後数日で死亡するものが多い。In acute cases of this disease, the onset temperature is 40-42℃.
Fever is present, and many patients die within a few days of onset.
このような重大な伝染病であるにもかかわらず、有効な
対策は殆んどなく、適切な飼育管理を行なうことなどの
対策がとられているが、実際には予防できないことが多
い。Despite the fact that it is such a serious infectious disease, there are almost no effective countermeasures, and although measures such as proper breeding management are taken, in reality it is often impossible to prevent it.
また、これまでに本疾病を予防及び治療するために、例
えば抗生物質やその他の抗閑剤を飼料と共に投与する方
法も行なわれている。しかし、近年特に耐性菌の発生や
動物への抗生物質等の残留性の問題などがあって、抗生
物質などの投与を家畜等の動物に対して行なうことは適
当でないという気運が高まりつつある。従って、抗生物
質などを用いない水痘の予防及び治療方法と治療剤の開
発が望まれている。Furthermore, in order to prevent and treat this disease, for example, methods have been used in which antibiotics and other antidepressants are administered together with feed. However, in recent years, there has been a growing trend that it is not appropriate to administer antibiotics to animals such as livestock due to problems such as the emergence of resistant bacteria and the persistence of antibiotics in animals. Therefore, it is desired to develop methods and therapeutic agents for preventing and treating chickenpox without using antibiotics.
[問題点を解決するための手段]
本発明者らは、上記の問題点を解決すべく研究した結果
、ある種の生薬に本疾病を抑制する効果がある事を見出
し、本発明を完成させた。[Means for Solving the Problems] As a result of research to solve the above problems, the present inventors discovered that certain herbal medicines have the effect of suppressing this disease, and completed the present invention. Ta.
即ち、本発明の目的は、豚のパスツレラ症の予防及び治
療剤並びに同庁の予防及び治療方法を提供することにあ
る。That is, an object of the present invention is to provide a preventive and therapeutic agent for pasteurellosis in pigs, as well as a preventive and therapeutic method according to the same agency.
本発明は、ダイオウ、オウレン、オウバク、オウゴン、
ゲンノショウコ、カンゾウ、エンメイソウ、チユ、ホッ
プ、ギュウタン、サンシュユ、ゴバイシ、タンジン、コ
オウレン、アロエ、チョウジ及びウバイからなる群から
選択された1種または2種以上の生薬を含有する豚のパ
スツレラ症の予防及び治療剤を提供するものである。The present invention relates to rhubarb, rhubarb, rhubarb, rhubarb, scutellariae,
Prevention of pasteurellosis in pigs containing one or more herbal medicines selected from the group consisting of Gennoshoko, Licorice, Trifolium, Chiyu, Hop, Gyutan, Cornelia, Gobaishi, Danjin, Kooren, Aloe, Clove and Ubai. It provides a therapeutic agent.
本発明は、また原末の形態の生薬、有機溶剤、有機溶剤
と水との混合物または水で抽出して得られる生薬エキス
、または生薬有効成分を含有する上記の豚のパスツレラ
症の予防及び治療剤を提供するものである。The present invention also provides the prevention and treatment of pasteurellosis in pigs containing the herbal medicine in the form of a bulk powder, an organic solvent, a mixture of an organic solvent and water, or a herbal medicine extract obtained by extraction with water, or an active ingredient of the herbal medicine. The purpose is to provide an agent for
本発明はまた生薬を飼料中に配合してなる豚のパスツレ
ラ症の予防及び治療剤を提供するものである。The present invention also provides a preventive and therapeutic agent for pasteurellosis in pigs, which is prepared by incorporating a herbal medicine into feed.
更に本発明は、ダイオウ、オウレン、オウバク、オウゴ
ン、ゲンノショウコ、カンゾウ、エンメイソウ、チユ、
ホップ、ギュウタン、サンシュユ、ゴバイシ、タンジン
、コオウレン、アロエ、チョウジ及びウバイからなる群
から選択されたIFJまたは2種以上の生薬の有効量を
投与することからなる豚のパスツレラ症の予防及び治療
方法を提供するものである。Furthermore, the present invention relates to rhubarb, orientalis, orientalis, orientalis, orientalis, licorice, orchid,
A method for the prevention and treatment of pasteurellosis in pigs, which comprises administering an effective amount of IFJ or two or more crude drugs selected from the group consisting of hops, gyutan, cornelian, gobaishi, tanjin, kouji, aloe, clove, and ubai. This is what we provide.
本発明はまた、原末の形態の生薬、有機溶、剤、有機溶
剤と水との混合物または水で抽出して得られる生薬エキ
ス、または生薬有効成分の形態で投与することからなる
豚のパスツレラ症の予防及び治療方法を提供するもので
ある。The present invention also relates to pasteurella in pigs, which is administered in the form of a crude drug in the form of a bulk powder, an organic solution, an agent, a mixture of an organic solvent and water, or a crude drug extract obtained by extraction with water, or in the form of an active ingredient of a crude drug. The aim is to provide methods for preventing and treating the disease.
本発明はまた、生薬を飼料中に配合して投与することか
らなる豚のパスツレラ症の予防及び治療方法を提供する
ものである。The present invention also provides a method for preventing and treating pasteurellosis in pigs, which comprises administering a crude drug in feed.
ダイオウ(大黄)は、ダイオウ(Rheu■pa1ma
tum Linne またはR,of’f’1cln
ale Ba1llon)及び近縁植物の根茎の皮部を
ほとんど除去して縦割したものである。このものは成分
として、アントラキノン誘導体として、クリソファノー
ル、エモジン、エモジンモノメチルエーテル等を含み、
ヒトの健胃苦味、緩下、消炎薬として慢性胃腸病、消化
不良、便秘症に用いられている。Rhubarb (Rheu pa1ma) is Rheu pa1ma.
tum Linne or R, of'f'1cln
Ale Balllon) and related plants are cut vertically with most of the skin removed. This product contains chrysophanol, emodin, emodin monomethyl ether, etc. as anthraquinone derivatives,
It is used in humans as a bitter, laxative, and anti-inflammatory drug to treat chronic gastrointestinal diseases, indigestion, and constipation.
オウレン(黄連)は、オウレン(CoptlsJapo
nIca Maklno)の根茎から細根を焼去ったも
のである。このものは成分としてベルベリン、ノシルマ
チン等を含み、ヒトの健胃苦味、整腸薬として用いられ
ている。Ouren (Yellow Ren) is Ouren (CoptlsJapo)
The fine roots are burned off from the rhizome of N.Ica Maklno. This product contains berberine, nocilmatine, etc. as ingredients, and is used as a bitter and intestinal medicine for humans.
オウバク(黄柏)は、キハダ(Phel Iodend
ronasurense Ruprecht)またはそ
の他の開成他種植物の樹皮のコルク層を除いたものであ
る。このものは成分として、ベルベリン、パルマチン等
を含み、ヒトの健胃、整腸、収れん及び消炎薬として用
いられている。Yellowfin tuna (Pheel Iodend)
ronasurense Ruprecht) or other cultivated plants, with the cork layer removed. This product contains berberine, palmatine, etc. as ingredients, and is used as a stomachic, intestinal regulation, astringent, and anti-inflammatory drug for humans.
オウゴン(黄苓)は、コガネバナ(Seutel Ia
rlabalcalensis Georgi)のコル
ク皮を除いた根である。このものの成分は、オーゴニン
とパイカリンであり、ヒトの消炎、解熱薬とし°C用い
られている。Scutellariae (Seutel Ia)
rlabalcalensis Georgi) from which the cork skin has been removed. The ingredients of this product are ogonin and picalin, and it is used as an anti-inflammatory and antipyretic drug in humans.
ゲンノショウコは、ゲンノショウコ(Geranlum
nepalense Sweet)の夏期の茎葉である
。このものは成分としてタンニン、没食子酸、コハク酸
等を含み、ヒトの収れん薬として下痢、腹痛の治療に用
いられる。Gen no Shoko is Gen no Shoko (Geranlum).
nepalense Sweet) in summer. This product contains tannins, gallic acid, succinic acid, etc., and is used as an astringent for humans to treat diarrhea and abdominal pain.
カンゾウ(甘草)は、カンゾウ(Glycyrrhiz
aglabra Linne var、 gland
ull(’era Regel etllerder)
の根及び根茎をそのまままたはコルク皮を除いたもので
ある。このものは成分として、グリチルリチン、リキリ
チン、ブドウ糖、アスパラギン等を含み、ヒトの緩和、
鎮痙薬、袂痰薬として用いられている。Licorice (licorice) is
aglabra Linne var, grand
ul('era regel etllerder)
The roots and rhizomes are either intact or with the cork skin removed. This product contains glycyrrhizin, liquiritin, glucose, asparagine, etc. as ingredients, and has a soothing effect on humans.
It is used as an antispasmodic and sputum medicine.
エンメイソウ(延命草)は、ヒキオコシ(Isodon
japonica Hara)またはクロバナヒキオ
コシ(Isodon trichocarpus Ku
do)の茎葉である。Enmeiso (Enmeiso) is called Hikiokoshi (Isodon).
japonica Hara) or Isodon trichocarpus Ku
These are the stems and leaves of do).
このものは成分として、プレクトランチン及びエンメイ
ンを含み、ヒトの健胃苦味薬として消化不良、食欲不振
、腹痛等の治療に用いられる。This product contains plectrantin and enmain as ingredients, and is used as a bitter medicine for human stomach health to treat indigestion, anorexia, abdominal pain, etc.
チユ(地楡)は、ワレモコウ(Sangulsorba
oITlclnalls L、)の根部を採り乾燥させ
たものである。このものは成分として、タンニン(17
%)、サポニンを含み、ヒトの止血収れん薬として、吐
血、喀血、月経過多の治療に用いられる。Chiyu (earth elm) is Sangulsorba
oITlclnalls L.) was harvested and dried. This product contains tannins (17
%), contains saponin, and is used as a hemostatic astringent in humans to treat hematemesis, hemoptysis, and menorrhagia.
ホップは、ホップ(llumulus Lupulus
L1nn6 )の成熟した果穂である。このものは成
分として、タンニン、ツムロン、ルブロン等を含み、ビ
ールの醸造において、苦味及び芳香を附けるために必要
なものである。Hops are hops (Llumulus Lupulus)
This is a mature fruit panicle of L1nn6). This product contains tannins, tumuron, rubron, etc. as ingredients, and is necessary for imparting bitterness and aroma in beer brewing.
ギュウタン(牛腸)は、ウシ(Bostaurusdo
mesticus Gzelin)の胆のうをぶら下げ
て陰干しするか、または胆管を切開して胆汁を容器に入
れて密封貯蔵したものである。このものは成分として、
コール酸ナトリウム塩、ムコタンパク質、脂肪酸等を含
み、ヒトの黄痕、便秘、糖尿病、痔癒等の治療に古くか
ら用いられている。Gyutan (cow intestine) is a bovine intestine.
The gallbladder of G. mesticus Gzelin is hung to dry in the shade, or the bile duct is incised and the bile is stored in a container in a sealed container. As an ingredient, this
It contains sodium cholate, mucoprotein, fatty acids, etc., and has been used for a long time to treat yellow scars, constipation, diabetes, hemorrhoids, etc. in humans.
サンシュユ(山菜英)は、サンシュユ(Cornuso
f’f’1clnalis 5iebold et Z
ucearini)の成熟した果実から種子を抽いたも
のである。このものは成分として結晶性の有機酸、没食
子酸、リンゴ酸、酒石酸等を含み、ヒトの滋養、強壮、
収れん薬として用いられている。Cornuso (cornuso)
f'f'1clnalis 5iebold et Z
Seeds are extracted from the mature fruits of P. ucearini). This product contains crystalline organic acids, gallic acid, malic acid, tartaric acid, etc. as ingredients, and is nourishing and tonic for humans.
It is used as an astringent.
ゴバイシ(五倍子)は、ヌルデノミミフシアブラムシ(
Melaphls chlnensls J、 Be1
l)の刺傷により主としてヌルデ(Rhus java
nica Linne )の葉に生じたゴールであって
、成分としてタンニン、没食子酸、脂肪、樹脂等を含む
。五倍子チンキ、タンニン酸、没食子酸、ピロガロール
の製造原料とされる。Gobaishi (Gobaishi) is the aphid (Nurudenomimifushia aphid)
Melaphls chlnensls J, Be1
The sting of Rhus java
It is a gall produced on the leaves of Nica Linne, and contains tannin, gallic acid, fat, resin, etc. as components. It is used as a raw material for the production of five-fold tincture, tannic acid, gallic acid, and pyrogallol.
タンジン(丹参)はタンジン(SalvIaa+1lt
iorrhiza Bunge)の根である。このもの
は成分として、タンジノンI、 II、クリプトタン
ジノンを含み、ヒトの強壮、通経、婦人票として月経不
調、子宮出血、腹痛及び諸瘉に用いられる。Dangjin (Danjin) is Dangjin (SalvIaa+1lt
iorrhiza Bunge). This product contains tandinone I, II, and cryptotandinone as ingredients, and is used for human tonicity, menstruation, and as a feminine aid for menstrual disorders, uterine bleeding, abdominal pain, and various types of chiasma.
コオウレン(胡黄連)は、コオウレン
(Plcrorrhiza Kurooa Royle
ex Benth、)の根茎である。このものは、成
分としてクトキン、D−マンニトール、バニリン酸等を
含み、ヒトの苦味健胃、緩下剤として用いられている。Plcrorrhiza Kurooa Royle is Plcrorrhiza Kurooa Royle.
ex Benth,). This product contains ingredients such as kutokin, D-mannitol, and vanillic acid, and is used as a bitter stomachic and laxative for humans.
アロエは、アロエ(Aloe arborescens
Mlll。Aloe is Aloe arborescens.
Mllll.
var、 natalensls Bergel、)の
粘液を煮つめたものである。このものは成分として、バ
ルバロイン、アロエーエモジン等を含み、中東やヨーロ
ッパで、非常に古くから苦味健胃薬または下剤として用
いられている。var, natalensls Bergel,) is boiled down. This product contains barbaroin, aloe emodin, etc. as ingredients, and has been used as a bitter stomachic or laxative for a very long time in the Middle East and Europe.
チョウジ(丁子)は、チョウジ(Eugeniacar
yophyllata Thunb、)の開花直前のつ
ぼみである。このものは成分として、オイゲノール、ア
セチルオイゲノール等を含み、ヒトの消化機能促進、駆
虫薬として、また香辛料、化粧品としても用いられてい
る。Clove is clove (Eugeniacar).
yophyllata Thunb,) just before flowering. This product contains components such as eugenol and acetyl eugenol, and is used to promote human digestive function, as an anthelmintic, and as a spice and cosmetic.
ウバイ(烏梅)は、ウメ(Prunus Muse 5
ieboldet Zuccarlnl)の未熟の果実
から果皮を剥いで煤煙中に埋めて乾燥したものである。Prunus Muse 5
The fruit is peeled off from the unripe fruit of A. ieboldet Zuccarlnl and buried in soot to dry.
このものは成分として、コハク酸、クエン酸、リンゴ酸
、酒石酸等を含みヒトの清涼性収れん薬、上湯、姐虫駆
除、解熱薬等として用いられる。This product contains ingredients such as succinic acid, citric acid, malic acid, and tartaric acid, and is used as a refreshing astringent, hot water, insect repellent, antipyretic, etc. for humans.
上記したように、本発明で用いる生薬のダイオウ、オウ
レン、オウバク、オウゴン、ゲンノショウコ、カンゾウ
、エンメイソウ、チユ、ホップ、ギュウタン、サンシュ
ユ、ゴバイシ、タンジン、コオウレン、アロエ、チョウ
ジ及びウバイの夫々は、それらを単独でか、または組合
わせてヒトの疾病の予防及び治療のために従来から使用
されていたものであるが、これらを豚の疾病の予防及び
治療の目的、殊に豚の感染症の予防及び治療の目的で使
用する試みはこれまでになされたことがなかった。As mentioned above, each of the crude drugs used in the present invention, rhubarb, orensis, aspergillus, aspergillus, gennoshoko, licorice, daylily, chiyu, hop, gyutan, cornelian, gobaishi, tanjin, kooren, aloe, clove, and ubai Traditionally used alone or in combination for the prevention and treatment of human diseases, they are now being used for the prevention and treatment of diseases in pigs, especially for the prevention and treatment of infectious diseases in pigs. No attempt has ever been made to use it for therapeutic purposes.
本発明者らは上記した生薬の薬効に着目して種々研究を
行なった結果、豚のパスツレラ症即ち豚が細菌のPa5
teurella multocidaに感染すること
によって発生する疾病の予防及び治療に上記した生薬の
1種または2種以上を組合わせて投与することがきわめ
て有効であることを見出し、本発明を完成したのである
。The present inventors conducted various studies focusing on the medicinal effects of the above-mentioned herbal medicines, and as a result, we found that pigs with pasteurellosis, that is, pigs are infected with bacterial Pa5.
The present invention was completed based on the discovery that it is extremely effective to administer one or more of the above-mentioned crude drugs in combination for the prevention and treatment of diseases caused by infection with Teurella multocida.
即ち、下記するように、上記した特定の種類の生薬及び
その抽出物が、インビトロ及びインビボにおいて細菌P
a5teurella multocidaに対し特異
的に静菌作用及び殺菌作用があることが明らかになった
。そしてこのPa5Leurella mulLoci
daに対する抑制効果の結果、上記した生薬を豚に投与
した場合にPa5teurel Ia Ifiulto
cld、aに由来する豚の疾病であるパスツレラ症を予
防及び治癒することができたのである。That is, as described below, the above-mentioned specific types of herbal medicines and their extracts are effective against bacterial P in vitro and in vivo.
It was revealed that it has bacteriostatic and bactericidal effects specifically against a5teurella multocida. And this Pa5Leurella mulLoci
As a result of the inhibitory effect on da, when the above-mentioned herbal medicines were administered to pigs,
It was possible to prevent and cure pasteurellosis, a disease of pigs caused by CLD, a.
そしてこの豚に特有の疾病に対して上記した特定の生薬
及びその抽出物が有効であることは予想もしえなかった
ことで、本発明者らによってはじめて明らかにされたこ
とである。The effectiveness of the above-mentioned specific herbal medicines and their extracts against this disease unique to pigs was unexpected and was revealed for the first time by the present inventors.
これら生薬は原末そのまままたは抽出エキス、生薬有効
成分の形態で直接投与したり、またこれらのものを飼料
に添加したりあるいは溶液製剤、分散製剤、半固形製剤
、粉粒体製剤、成型製剤、浸出製剤、注射用製剤等に製
剤化して使用する。These herbal medicines can be directly administered in the form of raw powder, extracts, or active ingredients of herbal medicines, or they can be added to feed, or they can be administered as solution preparations, dispersion preparations, semi-solid preparations, powder preparations, molded preparations, etc. It is used in formulations such as infusion preparations and injection preparations.
抽出エキスは、例えば、水、有機溶剤または水と有機溶
剤との混合物を使用して溶剤抽出し、それをそのままか
、濃縮してか、希釈してか、または溶剤を除去して用い
られる。The extract is used, for example, by solvent extraction using water, an organic solvent, or a mixture of water and an organic solvent, and used as it is, concentrated, diluted, or after removing the solvent.
有機溶剤としては、例えばメタノール、エタノール、n
−プロパツール、n−ブタノール、アセトン、酢酸エチ
ル、エーテル、塩化メチレン、クロロホルム、ベンゼン
、四塩化炭素、石油エーテル等が使用され、特にメタノ
ール、エタノールが望ましい。これらの有機溶剤は1種
または2種以上の混合物として用いることができる。Examples of organic solvents include methanol, ethanol, n
-Propertool, n-butanol, acetone, ethyl acetate, ether, methylene chloride, chloroform, benzene, carbon tetrachloride, petroleum ether, etc. are used, and methanol and ethanol are particularly preferred. These organic solvents can be used alone or as a mixture of two or more.
この溶剤抽出は、生薬をこれらの溶剤に冷浸または温浸
して行なうことができる。冷浸の場合には15〜25℃
、温浸の場合は35〜45℃の温度範囲で行なうことが
できる。抽出時間は、抽出温度によって異なるが、−殻
内には約5日間または可溶性成分が充分に溶けるまでと
する。This solvent extraction can be carried out by cold soaking or digesting the herbal medicine in these solvents. 15-25℃ for cold soaking
Digestion can be carried out at a temperature range of 35-45°C. The extraction time will vary depending on the extraction temperature, but may be approximately 5 days or until the soluble components are fully dissolved in the shell.
生薬有効成分は、例えば、上記抽出エキスをさらに各種
溶剤を用いて振盪し、この溶剤に移行する画分を採り出
し、その溶剤を留去したものを有効画分、即ち有効成分
として用いることもできる。The active ingredients of herbal medicines can be obtained by, for example, shaking the above-mentioned extract using various solvents, collecting the fraction that migrates to the solvent, and distilling off the solvent, which can be used as the effective fraction, that is, the active ingredient. can.
この場合に使用される溶剤は、非極性溶剤例えば、低級
脂肪族エーテル類(ジエチルエーテル、エチルメチルエ
ーテル等);低級ハロゲンアルカン類(クロロホルム、
ジクロルエタン、ジブロモエタン等);ベンゼン類(ベ
ンゼン、トルエン、キシレン等);その他の石油系溶剤
(石油エーテル、石油ベンゼン、リグロイン等)等が例
としてあげられる。Solvents used in this case include nonpolar solvents such as lower aliphatic ethers (diethyl ether, ethyl methyl ether, etc.); lower halogen alkanes (chloroform, ethyl methyl ether, etc.);
Examples include dichloroethane, dibromoethane, etc.); benzenes (benzene, toluene, xylene, etc.); and other petroleum solvents (petroleum ether, petroleum benzene, ligroin, etc.).
また、この有効画分を採り出した残りの水溶液を、水及
びある種の有機溶剤に水を飽和させたものを使用するこ
とにより振盪抽出し、水洗し、残分である有機溶剤層に
移行する画分の溶剤を留去したものも、有効画分即ち有
効成分として用いることができる。この有効画分は上記
の有効画分とは、物理化学的性質が異なり、検出される
成分も異なるものである。In addition, the remaining aqueous solution from which this effective fraction was extracted is extracted by shaking using water and a kind of organic solvent saturated with water, washed with water, and transferred to the organic solvent layer that is the residue. A fraction obtained by distilling off the solvent can also be used as an effective fraction, that is, an active ingredient. This effective fraction has different physicochemical properties and different detected components from the above-mentioned effective fraction.
投与量は、生薬の原末重量で換算して0.001gg/
体重kg1日〜100K/体重kg/日の範囲である。The dose is 0.001 gg/calculated as the weight of the raw drug powder.
Body weight kg/day ranges from 100K/kg body weight/day.
この量は、予防剤として用いる場合と治療剤として用い
る場合では異なり、−殻内には後者の方が投与量は多く
なる。This amount will be different for use as a prophylactic agent and as a therapeutic agent - the dose in the shell will be higher in the latter case.
投与方法は、経口投与または非経口投与することができ
、非経口投与としては筋肉内投与、腹腔内投与、経皮投
与、経鼻投与、静脈内投与等が可能である。The administration method can be oral or parenteral administration, and examples of parenteral administration include intramuscular administration, intraperitoneal administration, transdermal administration, nasal administration, intravenous administration, and the like.
[発明の効果]
以上詳述したように、本発明によれば豚のパスツレラ症
の有効な予防及び治療剤並びに有効な予防及び治療方法
が提供される。[Effects of the Invention] As detailed above, the present invention provides an effective preventive and therapeutic agent and an effective preventive and therapeutic method for pasteurellosis in pigs.
本発明の予防及び治療剤は生薬またはそれから得られる
エキス等を生薬とするため、抗生物質等の場合の耐性菌
の発生や副作用の問題が全くなく、安心して投与するこ
とができる。Since the prophylactic and therapeutic agent of the present invention uses herbal medicines or extracts obtained from them as herbal medicines, there is no problem of the development of resistant bacteria or side effects associated with antibiotics, etc., and it can be administered with confidence.
また、薬剤の残留による人体への影響の心配がないため
、内用豚に対するパスツレラ、症の予防及び治療のため
の薬物として適当である。In addition, since there is no concern about the effects of residual drug on the human body, it is suitable as a drug for the prevention and treatment of Pasteurella in pigs.
さらに、抗生物質等を用いる場合に比べて、安価に同疾
病を予防及び治療することができる。Furthermore, the disease can be prevented and treated at a lower cost than when using antibiotics or the like.
以下本発明を試験例及び実施例によりさらに詳しく説明
する。The present invention will be explained in more detail below using test examples and examples.
試験例 l
Pa5teurella ll1ultocldaの各
種生薬に対する感受性を調べた。Test Example 1 The sensitivity of Pa5teurella llultoclda to various crude drugs was investigated.
各種生薬を、生薬に対し7倍量の50%エタノール水溶
液中に加え、16時間抽出してアルコール抽出物とした
。Various crude drugs were added to a 50% aqueous ethanol solution in an amount seven times the amount of the crude drugs, and extracted for 16 hours to obtain alcoholic extracts.
また前記50%エタノール水溶液に代えて7〜15倍量
の水を使用し、これを100℃の温浴下で1時間抽出し
たものを水抽出物とした。Moreover, 7 to 15 times the amount of water was used in place of the 50% ethanol aqueous solution, and this was extracted in a hot bath at 100° C. for 1 hour to obtain a water extract.
抽出物を直径8龍のディスクに25μiずつしみ込ませ
乾燥させた。このディスクをPa5teurcl Ia
IIultocidaの菌株を塗った血液寒天培地に置
き37℃で18時間培養した後阻止円の直径を測定した
。The extract was infiltrated into an 8-diameter disk in an amount of 25 μi each and dried. This disc is Pa5teurcl Ia
The plate was placed on a blood agar medium coated with a strain of IIultocida and incubated at 37°C for 18 hours, after which the diameter of the inhibition zone was measured.
次にその試験結果を示せば表1及び表2のとおりである
。Next, the test results are shown in Tables 1 and 2.
表 1
ダ イ オ ウ 18
オ ウ し ン 27
オ ウ バ り 19オ
ウ ゴ ン 13ゲ
ンノシヨウコ 11
カ ン ゾ ウ 9エ
ンメイソウ 15
チ ュ 12ホ
ッ プ 12ギユウタン
15
サンシュユ 11
表 1 (続き)
ゴ バ イ シ 17
タ ン ジ ン IO
コオウレン IO
ア ロ エ 14
チ ョ ウ ジ 16
ウ バ イ 1
5表 2
生 薬 名 水抽出物による阻止円(mm)ダ イ
オ ウ 17オ ウ
し ン 21オ ウ
バ り 11エンメイ
ソウ 11
ギュウタン 14
ゴ バ イ シ 13
ア ロ エ 1
1実施例 1
基礎飼料
とうもろこし 250重量部
マ イ ロ
492 〃ふ す ま
35〃脱 脂 米 糠
35 l’大 豆 粕
85〃な た ね 粕
40 〃綿 実 粕
lO〃魚 粉 (60%)
5 〃肉 骨 粉 l
O〃糖 密 20〃
炭酸カルシウム 11〃
食 塩 3 〃プ
レミックス 4〃
前記基礎飼料にオウレン粉末を重量比で2%添加し供試
飼料とした。この供試飼料を60日令の健康豚80頭に
自由給餌させ180日令まで飼育した。Table 1 18
Oh Shin 27
Oubari 19 Ogon 13 Gennosyouko 11 Kanzo 9 Enmeiso 15 Chu 12 Ho
Table 1 (Continued) Gobaishi 17
Tanjin IO
Koouren IO aroe 14
Cho Ji 16
Bye bye 1
5 Table 2 Herbal medicine name Inhibition circle by water extract (mm) Daiou 17 Oushin 21 Obari 11 Enmeiso 11 Gyutan 14 Gobaishi 13
aroe 1
1 Example 1 Basic feed corn 250 parts by weight Milo
492
35 Defatted rice bran
35 l'soybean meal
85〃Na Tane Kasu
40 Cotton seed lees
lO〃Fish meal (60%)
5 〃Meat bone powder l
O〃Sugar dense 20〃
Calcium carbonate 11 Salt 3 Premix 4 2% by weight of Oren powder was added to the basic feed to prepare a test feed. This test feed was fed ad libitum to 80 healthy pigs aged 60 days and raised until they were 180 days old.
なお対照区は前記供試飼料の代りに基礎飼料を与えた。In the control group, basal feed was given instead of the above-mentioned test feed.
前記飼育期間中野外感染でのパスツレラによる肺炎症状
を呈した頭数及び肺炎により死亡した頭数を観察した。During the breeding period, the number of animals exhibiting pneumonia symptoms due to Pasteurella infection in the field and the number of animals dying from pneumonia were observed.
その結果試験区ではパスツレラによる肺炎症状を呈した
豚は1頭(0頭)780頭であったのに対し、対照区に
あっては20頭(18頭)780頭であった。なお前記
()内の数値はパスツレラによる肺炎で死亡した頭数を
示す。As a result, in the test area, 1 (0) 780 pigs exhibited pneumonia symptoms due to Pasteurella, while in the control area, the number was 20 (18) 780 pigs. The numbers in parentheses above indicate the number of animals that died from pneumonia caused by Pasteurella.
実施例 2〜17
実施例2〜17においてオウレンの代りに下記衣に示す
生薬を用いた以外は実施例1と同様に行なった。Examples 2 to 17 The same procedure as in Example 1 was conducted except that in Examples 2 to 17, the herbal medicine shown below was used instead of Oren.
次にその試験結果を示せば下表のとおりである。Next, the test results are shown in the table below.
(以下余白)
パスツレラによる
2 ダイ オ ウ 1頭(0)/80頭20頭(18)
/80頭3 オ ウ バ り 2頭(1)/80頭2
0頭(18) /80頭4 オ ウ ゴ ン 2頭(1
)/80頭20頭(18) /80頭5 ゲンノショ
ウコ 2頭(2)780頭 20頭(18) /80頭
6 カ ン ゾウ 3頭(3)/80頭20頭(18)
/80頭7 エンメイソウ 3頭(1)/80頭2
0頭(18) /80頭8 チ ュ 3頭(
3)780頭 20頭(18) /80頭9 ホ
ッ プ 4頭(3)780頭 20頭(1g) /8
0頭10 ギュウタン2頭(1)/80頭20頭(1
B) /80頭11 サンシュユ3頭(3)/80頭
20頭(18) /80頭12 ゴバ イ シ 3頭
(2)/80頭20頭(18) /80頭13 タ
ン ジ ン 4頭(4)/81)頭 20頭(18)
/80頭14 ニオ9123頭(3)/80頭20
頭(18) /80頭15 7 ロ エ 1頭(
1)780頭 20頭(18) /80頭16 チ
ョ ウ ジ 2頭(2)780頭 20頭(1B) /
80頭17 ウ バ イ 2頭(2)780頭
20頭(18) 780頭なお上記表中()内の数値
はパスツレラによる肺炎で死亡した頭数を示す。(Left below) Pasteurella 2 Daio cormorant 1 head (0) / 80 heads 20 heads (18)
/ 80 heads 3 Over 2 heads (1) / 80 heads 2
0 head (18) /80 head 4 Ougon 2 head (1
) / 80 heads 20 heads (18) / 80 heads 5 Genno Shoko 2 heads (2) 780 heads 20 heads (18) / 80 heads 6 Kan Elephant 3 heads (3) / 80 heads 20 heads (18)
/ 80 heads 7 Enmeiso 3 heads (1) / 80 heads 2
0 (18) / 80 8 Chu 3 (
3) 780 20 (18) / 80 9
Up 4 (3) 780 20 (1g) /8
0 head 10 Gyutan 2 head (1) / 80 head 20 head (1
B) /80 heads 11 Cornelius 3 heads (3) /80 heads 20 heads (18) /80 heads 12 Gobaishi 3 heads (2) /80 heads 20 heads (18) /80 heads 13 Tan Jin 4 heads (4)/81) 20 (18)
/ 80 heads 14 Nio 9123 heads (3) / 80 heads 20
Head (18) / 80 heads 15 7 Roe 1 head (
1) 780 20 (18) /80 16
2 (2) 780 20 (1B) /
80 17 U Bai 2 (2) 780 20 (18) 780 The numbers in parentheses in the table above indicate the number of animals that died from pneumonia caused by Pasteurella.
実施例 18
ダイオウ、オウレン、オウバク、オウゴン、ゲンノショ
ウコ、カンゾウ、エンメイソウ、チユ、ホップ、ギュウ
タン、サンシュユ、ゴバイシ、タンジン、コオウレン、
アロエ、チョウジ及びウバイの各々の粉末を1kgとり
、これをそれぞれ10IIの水に入れ100℃で1時間
抽出した。各々の水抽出物を1000倍に希釈し、試験
抽出エキスとした。試験区、対照区とも、各区夫々60
日令の豚を30頭ずつ使用し、対照区には水を、試験区
は試験抽出エキスを水の代りに給与した。飼料は対照区
試験区ともに、実施例1で使用したものと同じ基礎飼料
を用いた。このようにして180日令になるまで飼育し
、その期間中の野外感染のパスツレラによる肺炎を呈し
た頭数及び死亡した頭数を観察した。その結果すべての
試験区で対照区よりパスツレラによる野外感染により肺
炎を呈した頭数及び死亡した頭数が少かった。Example 18 Rhubarb, orientalis, orientalis, orientalis, gennoshoko, licorice, daylily, chiyu, hop, gyutan, cornelian, gobaishi, tanjin, orensis,
1 kg of each powder of aloe, clove, and ubai was taken, and each powder was added to 10 II of water and extracted at 100° C. for 1 hour. Each water extract was diluted 1000 times to prepare a test extract. 60 each for both test and control areas.
Thirty day-old pigs were used, and the control group was given water, and the test group was given the test extract instead of water. The same basal feed as that used in Example 1 was used for both the control and test plots. The animals were raised in this manner until they were 180 days old, and the number of animals that developed pneumonia due to field-infected Pasteurella and the number of animals that died during that period was observed. As a result, the number of animals that developed pneumonia and died due to field infection with Pasteurella was lower in all test plots than in the control plots.
Claims (1)
ショウコ、カンゾウ、エンメイソウ、チユ、ホップ、ギ
ュウタン、サンシュユ、ゴバイシ、タンジン、コオウレ
ン、アロエ、チョウジ及びウバイからなる群から選択さ
れた1種または2種以上の生薬を含有する豚のパスツレ
ラ症の予防及び治療剤。 2)生薬が原末の形態である特許請求の範囲第1項に記
載の予防及び治療剤。 3)生薬が有機溶剤、水と有機溶剤との混合物または水
で抽出した生薬エキス及び/またはそれから得られた生
薬有効成分である特許請求の範囲第1項に記載の予防及
び治療剤。4)生薬が飼料中に配合されてなる特許請求
の範囲第1項に記載の予防及び治療剤。 5)ダイオウ、オウレン、オウバク、オウゴン、ゲンノ
ショウコ、カンゾウ、エンメイソウ、チユ、ホップ、ギ
ュウタン、サンシュユ、ゴバイシ、タンジン、コオウレ
ン、アロエ、チョウジ及びウバイからなる群から選択さ
れた1種または2種以上の生薬の有効量を投与すること
からなる豚のパスツレラ症の予防及び治療方法。 6)生薬が原末の形態で用いられる特許請求の範囲第5
項に記載の予防及び治療方法。 7)生薬が有機溶剤、水と有機溶剤との混合物または水
で抽出した生薬エキス及び/またはそれから得られた生
薬有効成分である特許請求の範囲第5項に記載の予防及
び治療方法。 8)生薬が飼料に混合して投与される特許請求の範囲第
5項に記載の予防及び治療方法。[Scope of Claims] 1) One species selected from the group consisting of rhubarb, orientalis, orientalis, scutellariae, scutellariae, licorice, daylily, chiyu, hop, gyutan, cornelian, burr, chinsugar, trumpet, aloe, clove, and urba. Or a preventive and therapeutic agent for pasteurellosis in pigs containing two or more kinds of herbal medicines. 2) The prophylactic and therapeutic agent according to claim 1, wherein the crude drug is in the form of bulk powder. 3) The prophylactic and therapeutic agent according to claim 1, wherein the crude drug is an organic solvent, a mixture of water and an organic solvent, a crude drug extract extracted with water, and/or a crude drug active ingredient obtained therefrom. 4) The prophylactic and therapeutic agent according to claim 1, wherein the crude drug is blended into the feed. 5) One or more herbal medicines selected from the group consisting of rhubarb, orientalis, orientalis, scutellariae, scutellariae, licorice, daylily, chiyu, hop, gyutan, cornshuyu, gobaishi, tanjin, orientalis, aloe, clove, and ubai. A method for preventing and treating pasteurellosis in pigs, comprising administering an effective amount of. 6) Claim 5 in which the crude drug is used in the form of bulk powder
Prevention and treatment methods described in Section. 7) The prevention and treatment method according to claim 5, wherein the herbal medicine is an organic solvent, a mixture of water and an organic solvent, a herbal medicine extract extracted with water, and/or an active herbal medicine ingredient obtained therefrom. 8) The prevention and treatment method according to claim 5, wherein the herbal medicine is mixed with feed and administered.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62328322A JP2599152B2 (en) | 1987-12-26 | 1987-12-26 | Agent for prevention and treatment of pasturellosis in pigs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62328322A JP2599152B2 (en) | 1987-12-26 | 1987-12-26 | Agent for prevention and treatment of pasturellosis in pigs |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01172334A true JPH01172334A (en) | 1989-07-07 |
JP2599152B2 JP2599152B2 (en) | 1997-04-09 |
Family
ID=18208945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62328322A Expired - Lifetime JP2599152B2 (en) | 1987-12-26 | 1987-12-26 | Agent for prevention and treatment of pasturellosis in pigs |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2599152B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01285160A (en) * | 1988-05-12 | 1989-11-16 | Itochu Shiryo Kk | Feed for hog-raising |
US6641851B2 (en) * | 2001-02-12 | 2003-11-04 | The Himalaya Drug Company | Herbal laxative preparation |
KR101398426B1 (en) * | 2007-03-16 | 2014-06-18 | 원광대학교산학협력단 | A composition comprising extracts of Galla Rhois and Moutan Cortex Radicis showing antibacterial and antiviral activity |
CN105030929A (en) * | 2015-08-21 | 2015-11-11 | 潍坊华英生物科技有限公司 | Traditional Chinese medicinal composition for preventing and treating seasonal febrile diseases of poultry and livestock |
CN107646733A (en) * | 2017-10-20 | 2018-02-02 | 贵州松羽禽业有限公司 | A kind of poultry feed of pre- avian influenza-prevention |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101008463B1 (en) * | 2007-12-28 | 2011-01-14 | 원광대학교산학협력단 | A veterinary composition comprising extract of Galla Rhois or the compounds isolated therefrom showing antibacterial and antiviral activity |
KR101008480B1 (en) * | 2007-12-28 | 2011-01-14 | 원광대학교산학협력단 | A composition comprising the extract of Galla Rhois or the compounds isolated therefrom showing antibacterial activity |
-
1987
- 1987-12-26 JP JP62328322A patent/JP2599152B2/en not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01285160A (en) * | 1988-05-12 | 1989-11-16 | Itochu Shiryo Kk | Feed for hog-raising |
JPH0466530B2 (en) * | 1988-05-12 | 1992-10-23 | Itochu Shiryo Kk | |
US6641851B2 (en) * | 2001-02-12 | 2003-11-04 | The Himalaya Drug Company | Herbal laxative preparation |
KR101398426B1 (en) * | 2007-03-16 | 2014-06-18 | 원광대학교산학협력단 | A composition comprising extracts of Galla Rhois and Moutan Cortex Radicis showing antibacterial and antiviral activity |
CN105030929A (en) * | 2015-08-21 | 2015-11-11 | 潍坊华英生物科技有限公司 | Traditional Chinese medicinal composition for preventing and treating seasonal febrile diseases of poultry and livestock |
CN107646733A (en) * | 2017-10-20 | 2018-02-02 | 贵州松羽禽业有限公司 | A kind of poultry feed of pre- avian influenza-prevention |
CN107646733B (en) * | 2017-10-20 | 2020-11-10 | 贵州松羽禽业有限公司 | Prevent bird flu's fodder of raising chickens and feed and eat equipment |
Also Published As
Publication number | Publication date |
---|---|
JP2599152B2 (en) | 1997-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2599161B2 (en) | Preventive and therapeutic agent for Clostridium perfringens infection in livestock and poultry | |
JP2599159B2 (en) | Prevention and treatment of bovine mastitis | |
JP2603977B2 (en) | Prevention and treatment of Pasteurella haemolytica infection in livestock | |
Akbar et al. | Glycyrrhiza glabra L.(Fabaceae/Leguminosae) (Syns.: G. glandulifera Waldst. & Kit.; G. hirsuta Pall.; G. pallida Boiss. & Noe; G. violacea Boiss. & Noe) | |
JP2535559B2 (en) | Agent for the prevention and treatment of pruritus in fish | |
WO2020155318A1 (en) | Traditional chinese medicine preparation for treatment of bacterial respiratory tract disease in livestock and production technique thereof | |
JPH01172334A (en) | Preventive and remedy for swine pasteurellosis | |
JP2599160B2 (en) | Preventive and therapeutic agent for staphylococcal disease in chickens | |
Bandyopadhyay et al. | Medicinal pteridophytes: ethnopharmacological, phytochemical, and clinical attributes | |
JP2535555B2 (en) | Agent for preventing and treating streptococcal disease in fish | |
JPH01172333A (en) | Preventive and remedy for swine infectious diseases of streptococcus hemolyticus | |
JP2535557B2 (en) | Agent for preventing and treating Vibrio alderi infection of fish | |
Gaikwad et al. | Review on phytochemicals and pharmacological profile of Helicteres isora Linn | |
CN105497340A (en) | Hemorrhoid ointment, as well as preparation method and hemorrhoid ointment set thereof | |
JP2599157B2 (en) | Preventive and therapeutic agent for swine dysentery | |
JP2599154B2 (en) | Agent for prevention and treatment of haemophilus infection in pigs | |
JP2535553B2 (en) | Agent for preventing and treating bacterial nodule disease in fish | |
JP2535556B2 (en) | Agent for prevention and treatment of vibrio disease in fish | |
CN110404006A (en) | A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis | |
JPH01172339A (en) | Preventive and remedy for infectious disease of campylobacter jejuni of mammals | |
US11564967B1 (en) | Oral compositions containing extracts of a betel leaf and related methods | |
Keerthana et al. | Physiological and pharmacological activities of Terminalia bellerica. | |
Pandey et al. | Pharmacological efficacies of Asparagus racemosus: A | |
CN109908312B (en) | Hemorrhoid ointment and preparation method thereof | |
CN105395797A (en) | Chinese and western compound medicine composition for treating pike bacterial gill-rot disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |